New Therapeutic Options for Advanced Hepatocellular Carcinoma

Ma, Yu‐Shui; Liu, Ji‐Bin; Wu, Ting‐Miao; Fu, Da

doi:10.1177/1073274820945975

Cited by 16 publications

(5 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, molecular targeted therapy, such as lenvatinib, atezolizumab and bevacizumab, has emerged as a new cancer treatment method [ 32 ]. However, these treatment agents, except for sorafenib, were not reimbursed by Taiwan National Health Insurance (NHI) during the study period (2016–2019).…”

Section: Discussionmentioning

confidence: 99%

Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: To evaluate the effectiveness of hepatic arterial infusion chemotherapy (HAIC) followed by lipiodol infusion in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Materials and Methods: Thirty-two patients with advanced HCC and PVTT who received HAIC with regimens of cisplatin, mitomycin-C, and 5-fluorouracil followed by lipiodol infusion were enrolled. The primary efficacy endpoint was tumor response rate. The modified Response Evaluation Criteria in Solid Tumors (mRECIST) was used for assessment of treatment response. The secondary endpoints were overall survival (OS) and progression free survival (PFS). Prognostic factors for survival also were evaluated. Results: The median OS and PFS were 11.9 and 9.5 months, respectively. Seventeen patients (53.1%) achieved objective response, and 23 patients (71.9%) achieved disease control. The length of survival in the responder and disease control groups was longer than in the non-responder and progressive disease groups after two cycles of HAIC (responder vs. non-responder: 16.5 vs. 7.9 months, p = 0.001; disease control vs. progressive disease: 12.3 vs. 5.6 months, p < 0.001) and after completing HAIC (responder vs. non-responder: 15.7 vs. 6.9 months, p = 0.001; disease control vs. progressive disease: 13.6 vs. 6.9 months, p < 0.001). Better survival was associated with Child-Pugh A liver function (p = 0.013), with early response to two HAIC cycles (p = 0.009), and with response (p = 0.02) and disease control (p = 0.001) after completing HAIC treatment. Conclusion: HAIC followed by lipiodol infusion is a safe and feasible treatment for advanced HCC with PVTT. Patients with early response could continue HAIC treatment with expected prolonged survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Kinase inhibitors other than sorafenib, like Lenvatinib, cabozantinib, and regorafenib, showed some good results, but none were superior to sorafenib. 29 As HCC is known to be a highly vascular tumor, drugs that act as vascular endothelium growth factor inhibitors with different mechanisms have been investigated as bevacizumab and Ramucirumab. Multiple drug categories have been investigated like a-Fetoprotein Targeted Drugs, and Glypican-3 Targeted Drugs.…”

Section: Discussionmentioning

confidence: 99%

“…Multiple drug categories have been investigated like a-Fetoprotein Targeted Drugs, and Glypican-3 Targeted Drugs. 29 The liver is a central immunomodulator that keeps the balance between protection and immunotolerance. 30,31 Deregulation of the liver immunological network is a hallmark of chronic liver disease and HCC.…”

Section: Discussionmentioning

confidence: 99%

<p>Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries</p>

Abouelezz¹,

Khanapara²,

Batiha³

et al. 2020

CMAR

View full text Add to dashboard Cite

Systemic therapy options nowadays for advanced hepatocellular carcinoma (HCC) are either immunotherapy with immune checkpoint inhibitors or targeted therapy. As the incidence of liver cancer is much higher in developing countries, these new medications are not readily accessible for most of the patients. Cytotoxic chemotherapy agents are more available and affordable in developing countries. We are trying to explore the effectiveness of the newer cytotoxic agents in the systematic treatment for advanced HCC. This is a systematic review of all randomized controlled trials since 1997 that utilized systemic cytotoxic chemotherapy agents in the systemic treatment for advanced HCC using Scopus, PubMed, and Cochrane library up to February 2020. Six randomized trials were found. Different drugs and dosages were used, so it was statistically inappropriate to conduct a meta-analysis. No Phase III trial showed statistically significant overall survival (OS) benefit for cytotoxic chemotherapy, except subgroup analysis of Chinese patients in one study who had leucovorin, fluorouracil, and oxaliplatin (FOLFOX) regimen. There was no significant progression-free survival (PFS) or response rate in the Phase II trials. There are not enough data to infer the actual benefits of systemic cytotoxic chemotherapy in advanced HCC. However, oxaliplatin-based regimens may give feasible results. Health systems with limited access to targeted therapy and immunotherapy agents may use oxaliplatin-based regimens in clinical trials for advanced HCC. These results should be confirmed in multiple future randomized clinical trials.

show abstract

“…[41][42][43] UHRF1 is a ubiquitin E3 ligase and contains at least 4 domains including a plant homeodomain domain, a ubiquitin-like domain, a RING domain, and a SET and RING associated (SRA) domain. [44][45][46][47] It was confirmed that UHRF1 could co-locate with DNA methyltransferase protein DNMT1 in the S phase. 48 The SRA domain of UHRF1 strongly binds to the physiological substrate for DNMT1.…”

Section: Introductionmentioning

confidence: 88%

MiR-9-1 Suppresses Cell Proliferation and Promotes Apoptosis by Targeting UHRF1 in Lung Cancer

Jia

Xiang

Liu

et al. 2021

Technol Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Lung cancer is listed as the most common reason for cancer-related death all over the world despite diagnostic improvements and the development of chemotherapy and targeted therapies. MicroRNAs control both physiological and pathological processes including development and cancer. A microRNA-9 to 1 (miR-9 to 1) overexpression model in lung cancer cell lines was established and miR-9 to 1 was found to significantly suppress the proliferation rate in lung cancer cell lines, colony formation in vitro, and tumorigenicity in nude mice of A549 cells. Ubiquitin-like containing PHD and RING finger domains 1 (UHRF1) was then identified to direct target of miR-9 to 1. The inhibition of UHRF1 by miR-9 to 1 causes G1 arrest and p15, p16, and p21 were re-expressed in miR-9 to 1 group in mRNA level and protein level. Silence of UHRF1 expression in A549 cells resulted in the similar re-expression of p15, p16, p21 which is similar with miR-9 to 1 infection. Therefore, we concluded that UHRF1 is a new target for miR-9 to 1 to suppress cell proliferation by re-expression of tumor suppressors p15, p16, and p21 mediated by UHRF1.

show abstract

New Therapeutic Options for Advanced Hepatocellular Carcinoma

Cited by 16 publications

References 132 publications

Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience

Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience

<p>Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries</p>

MiR-9-1 Suppresses Cell Proliferation and Promotes Apoptosis by Targeting UHRF1 in Lung Cancer

Contact Info

Product

Resources

About